JNJ fundamental analysis

**Johnson & Johnson (JNJ) exhibits strong fundamentals**, as evidenced by its recent financial performance and strategic positioning in the healthcare industry. Here's a detailed analysis:

1. **Financial Performance**:
- JNJ reported a total revenue of $21.89 billion, with a net income of $11 billion and a diluted EPS of $4.54 in the latest quarter. The company has shown a significant increase in net income growth by 237.91% and a diluted EPS growth rate of 238.81%.

|code|Ticker|Name|Date|Total Revenue|Net Income|Diluted EPS|market_code|
|---|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q2|2.2447E10|4.686E9|1.93|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q3|2.2471E10|2.694E9|1.11|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q4|2.252E10|3.431E9|1.41|169|
|JNJ|JNJ.N|Johnson & Johnson|2025 Q1|2.1893E10|1.0999E10|4.54|169|

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q2|-8.90357698289269|4.312468051489382|-1.5306122448979604|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q3|-89.6496081143384|5.245655941173716|-89.128305582762|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q4|-15.263027908125462|5.258237906052816|-15.568862275449103|169|
|JNJ|JNJ.N|Johnson & Johnson|2025 Q1|237.91090629800306|2.385072253659449|238.8059701492537|169|

2. **Valuation Metrics**:
- The company's P/E ratio is 16.5, indicating a premium valuation compared to some peers. The P/S ratio is 4.14, suggesting a strong market valuation relative to its sales. The price to book ratio is 4.61, which may indicate a higher valuation by the market compared to its asset base.

|code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code|
|---|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|20240605|9.130443|4.107269330104639|5.017180239110397|169|
|JNJ|JNJ.N|Johnson & Johnson|20240606|9.158591|4.119931323655006|5.032647328975435|169|
|JNJ|JNJ.N|Johnson & Johnson|20240607|9.199874|4.138502247528878|5.055332394110826|169|
|JNJ|JNJ.N|Johnson & Johnson|20240610|9.203002|4.139909135701141|5.057050959651385|169|
|JNJ|JNJ.N|Johnson & Johnson|20240611|9.179858|4.129498163226395|5.044333574651242|169|
|JNJ|JNJ.N|Johnson & Johnson|20240612|9.095415|4.091512182575293|4.997932305056127|169|
|JNJ|JNJ.N|Johnson & Johnson|20240613|9.097917|4.092637693113104|4.999307157488574|169|
|JNJ|JNJ.N|Johnson & Johnson|20240614|9.103547|4.095170091823177|5.002400575461582|169|
|JNJ|JNJ.N|Johnson & Johnson|20240617|9.129192|4.106706574835734|5.016492812894173|169|
|JNJ|JNJ.N|Johnson & Johnson|20240618|9.110427|4.098265245802156|5.006181419650814|169|

3. **Cash Flow and Profitability**:
- JNJ has a positive free cash flow of $3.38 billion, with operating cash flow of $4.17 billion and financing and investing cash flows of -$297 million and $10.42 billion, respectively.

|code|Ticker|Name|Date|Free Cash Flow|Investing Cash Flow|Operating Cash Flow|Financing Cash Flow|market_code|
|---|---|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q2||-1.3687E10|5.633E9|7.544E9|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q3|2.0749233253E10|-3.128E9|7.993E9|-9.882E9|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q4|1.813563452E10|-1.32E9|6.983E9|-1.34E9|169|
|JNJ|JNJ.N|Johnson & Johnson|2025 Q1|5.501719233E9|-2.97E8|4.174E9|1.0422E10|169|

- The company's operating margin is 28.9%, with a gross margin of 66.4% and a net margin of 50.24%.

|code|Ticker|Name|Date|Gross Profit Margin|Operating Profit Margin|Net Profit Margin|market_code|
|---|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q2|69.473|28.90714122746977|18.1177|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q3|69.3172|26.918146030979923|16.0405|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q4|69.0715|24.335461208497993|15.8363|169|
|JNJ|JNJ.N|Johnson & Johnson|2025 Q1|66.3957|28.899648289407576|50.2398|169|

4. **Dividend and Shareholder Returns**:
- JNJ has a dividend yield of 3.27% and has a long history of dividend payments, with a continuous dividend duration of 45 years.
- The company's ROE is 14.7%, with an ROA of 7.23%.

|code|Ticker|Name|Date|Payout Ratio|Dividend Yield (TTM)|market_code|
|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|20240605|5.418383654614887|3.3612440912516273|169|
|JNJ|JNJ.N|Johnson & Johnson|20240606|4.343737563116268|3.350913809588854|169|
|JNJ|JNJ.N|Johnson & Johnson|20240607|4.343737563116268|3.3358770737013868|169|
|JNJ|JNJ.N|Johnson & Johnson|20240608|4.343737563116268||169|
|JNJ|JNJ.N|Johnson & Johnson|20240609|4.343737563116268||169|
|JNJ|JNJ.N|Johnson & Johnson|20240610|4.343737563116268|3.3347434241826956|169|
|JNJ|JNJ.N|Johnson & Johnson|20240611|4.343737563116268|3.343150722267648|169|
|JNJ|JNJ.N|Johnson & Johnson|20240612|4.343737563116268|3.3741888453338835|169|
|JNJ|JNJ.N|Johnson & Johnson|20240613|4.343737563116268|3.3732609144035752|169|
|JNJ|JNJ.N|Johnson & Johnson|20240614|4.343737563116268|3.3711749347258486|169|

|code|Ticker|Name|Date|ROA|ROE(Average)|market_code|
|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q2|5.2363|11.3191|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q3|7.1518|15.3096|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q4|9.2676|20.0565|169|
|JNJ|JNJ.N|Johnson & Johnson|2025 Q1|7.2252|14.7046|169|

5. **Market Position and Growth Prospects**:
- JNJ has been named as one of the top 25 dividend giants by ETF Channel, with a significant amount of stock held by ETFs.
- The company's diversified healthcare portfolio and strong cash flow position it well for acquisitions and to capitalize on market opportunities.
6. **Analyst Ratings and Price Target**:
- The consensus rating for JNJ is "Buy" with an average price target of $196.14, suggesting a potential upside from the current price.
7. **Strategic Positioning**:
- JNJ has a strong research and development focus, investing heavily in innovation while also making acquisitions to enhance its position.

In conclusion, JNJ's strong financial performance, strategic investments, and dominant market position in the healthcare industry support a positive fundamental analysis. However, investors should monitor the company's ability to manage potential risks associated with its large-scale investments and maintain its operating margins.